Contribution of PD-L1 to oncogenesis of lymphoma and its RNAi-based targeting therapy.
about
Recent advances in post autologous transplantation maintenance therapies in B-cell non-Hodgkin lymphomasRole of programmed death ligands in effective T-cell interactions in extranodal natural killer/T-cell lymphomaCombination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcomaB7-H3 silencing by RNAi inhibits tumor progression and enhances chemosensitivity in U937 cells.Microenvironment abnormalities and lymphomagenesis: Immunological aspects.Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial.Immune checkpoint inhibition in lymphoid disease.Novel immunologic approaches in lymphoma: unleashing the brakes on the immune system.Post-autologous transplant maintenance therapies in lymphoid malignancies: are we there yet?MYC: Master Regulator of Immune Privilege.Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies.Programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and EBV-encoded RNA (EBER) expression in Hodgkin lymphoma.Genomic alterations of the JAK2 and PDL loci occur in a broad spectrum of lymphoid malignancies.Effect of dihydroarteminin combined with siRNA targeting Notch1 on Notch1/c-Myc signaling in T-cell lymphoma cells.
P2860
Q26784108-2CEF2002-8422-4FFC-9C96-496FD5202003Q34141476-77454F2A-33A6-4DDB-982A-722A7718E2A7Q35624496-10799EBA-3FE7-4405-B77C-B93EC3E55843Q35867721-7DAAED0B-8955-4DF2-918C-0BBF3B35A4DEQ36118020-1E8CC5A0-8290-4D6F-9164-C5D51FFCF86FQ36929714-FBAB1F68-2922-42E6-AB64-84ECB205606BQ38396568-C94D0F47-8555-42A3-B75B-18E75E6BBA07Q38489700-FD41FFB2-C7B5-4EE1-B17D-A7884C8B5AC1Q38568358-B1CC7F70-A740-4BAD-B1B3-182F732530D6Q39149130-CC69C9B7-E3FB-4504-A92F-BFDE2D1EEAF8Q39237785-49490166-769D-41BE-B4C5-8F235509A5B3Q41719867-C037B8B6-046B-4B9B-84E6-DE520BE742C0Q54216481-127B3A18-C8FA-4E39-81A5-6C952FFB7015Q55093732-26F3400C-5EF7-4D1F-8ED8-6A457BC4FC15
P2860
Contribution of PD-L1 to oncogenesis of lymphoma and its RNAi-based targeting therapy.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Contribution of PD-L1 to oncogenesis of lymphoma and its RNAi-based targeting therapy.
@en
Contribution of PD-L1 to oncogenesis of lymphoma and its RNAi-based targeting therapy.
@nl
type
label
Contribution of PD-L1 to oncogenesis of lymphoma and its RNAi-based targeting therapy.
@en
Contribution of PD-L1 to oncogenesis of lymphoma and its RNAi-based targeting therapy.
@nl
prefLabel
Contribution of PD-L1 to oncogenesis of lymphoma and its RNAi-based targeting therapy.
@en
Contribution of PD-L1 to oncogenesis of lymphoma and its RNAi-based targeting therapy.
@nl
P2093
P2860
P1433
P1476
Contribution of PD-L1 to oncogenesis of lymphoma and its RNAi-based targeting therapy.
@en
P2093
P2860
P304
P356
10.3109/10428194.2012.673228
P577
2012-04-30T00:00:00Z